

Contents lists available at [ScienceDirect](http://www.sciencedirect.com)

Asian Pacific Journal of Tropical Biomedicine

journal homepage: www.elsevier.com/locate/apjtbReview article <http://dx.doi.org/10.1016/j.apjtb.2017.06.001>

An overview on application of phage display technique in immunological studies

Abbas Rami¹, Mahdi Behdani¹, Najmeh Yardehnabi^{2,3}, Mahdi Habibi-Anbouhi⁴, Fatemeh Kazemi-Lomedasht^{1*}¹Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab., Pasteur Institute of Iran, Tehran, Iran²Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran³Department of Medical Biotechnology, Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, Iran⁴National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran

ARTICLE INFO

Article history:

Received 23 May 2017

Received in revised form 28 May 2017

Accepted 19 Jun 2017

Available online 23 Jun 2017

Keywords:

Phage display

Antibody

Epitope mapping

Immunology

Antibody library

Peptide library

ABSTRACT

Phage display is very strong technique in drug discovery and development. Phage display has many applications in improving the immunological studies. Development of monoclonal antibody, peptides, peptidomimetics and epitope mapping are main application of phage display. Selection of monoclonal antibody or peptides that are displayed on the surface of the phages can be occurred through biopanning process. In biopanning process phage library is incubated with antigen and particular phages can be identified and isolated. Increasing the stringency in the biopanning rounds can be help to select phages with high affinity and specificity. Here, we describe an overview of phage display application with focusing on monoclonal antibody production and epitope mapping.

1. Introduction

Phage display is generally new strategy to exhibit peptide (polypeptides) on the surface of bacteriophage. For the first time, phage display introduced by George Smith in 1985. As per this system, phages can be expressed the desired (poly) peptides as a component of their surface proteins. In this technique, the (poly) peptide expresses as fusion with one of the surface proteins of the bacteriophage and in this way the desired (poly) peptide is chosen by binding to different target [1]. In fact, this method is based on the reaction between the ligand and receptor. Displaying of proteins on the surface of the phages is dependable strategy for choice of uncommon qualities that code proteins with binding activity. Phage display can be set to show different quantities of peptides with substantial differences in polyvalent configuration. The level of display

relies on upon the sequence and also length of poly (peptides) [2,3]. In case of small peptides (smaller than 8 residues), hundreds or thousands copies of them can be displayed [4,5]. This technology is fit for delivering small peptides (1–20 residues) with high binding affinity to any protein [6]. Phage display is based on genetic manipulation of genes of surface proteins of filamentous phages like M13 and Fd. Foreign DNA inter into the genome of filamentous phage (for example gene III) and foreign peptide encoded as a fusion protein with a surface coating protein [1,7,8].

Rapid identification and isolation of high specific phage to its own target (through biopanning process) is advantage of phage display technique. Biopanning causes recognizable proof of individual peptides in the scope of micromolar to nanomolar range [9,10]. In this review we outlined distinctive application of phage display from the past to present.

2. General view to biology of filamentous phages

Filamentous phages are group of non-lytic phages that incorporate round single stranded DNA. The family of Ff, M13, fd, and f1 are vital phages which have utility in phage display among which M13 phage is the most generally used [11]. M13

*Corresponding author: Fatemeh Kazemi-Lomedasht, Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab., Pasteur Institute of Iran, Tehran, Iran.
Tel: +98 2166480780
E-mail: fa_kazemi@pasteur.ac.ir (F. Kazemi-Lomedasht).

Peer review under responsibility of Hainan Medical University. The journal implements double-blind peer review practiced by specially invited international editorial board members.

phage, is a bacteriophage that is (6–7) nm in diameter and 900 nm long and is a member of F positive family [12]. The most important feature is that in contrast to other phages, M13 can be effortlessly purified and used. Replication of M13 phage initiates through binding of M13 to its receptor on the bacterial cell (bacterial F-pilus). Therefore bacterial cells that contain pili have infected with M13 phages [12]. In fact, bacterial cell acts as a production factory of M13 phages. M13 phages do not kill host cells but slow the cell growth due to stress in the production of phage particles. The genome of M13 phage is 6407 bp long that encodes three groups of phage proteins: 1 – proteins involving in replication (pII, pX and pV), 2 – morphogenetic (pI and pIV), and 3 – structural (pVIII, pIII, pVI, pVII and pIX). The coating proteins of phage categorized into major (pVIII) and minor (pIII and pVI) proteins. Each phage has about 2700 copies of pVIII. The N-terminal region of pIII plays important role in binding of phage to the F-pilus of the bacterium [13–15]. Infection process of bacterial cell initiates with binding of pIII of phage particles to F-pilus. Each phage contains three to five pIII proteins at one end [2,16]. Then single-stranded DNA with the help of cytoplasmic enzymes of bacterium converts to double-stranded DNA which is known as replicative form (RF). The protein pV of phage binds to single strand DNA and inhibits its conversion to replicative form. In fact the amount of pV play critical role for conversion of single strand DNA to RF [17]. Assembly of phage particles starts from inner membrane of bacterium with help of pI, pIV and pXI. pVII and pIX play role in secretion of phage. pV is replaced by pVIII during deprotection and then pVI and pIII are added to the end of the phage [18]. At the first generation of bacterial infection about 1000 phage particles are produced that decrease to 100 to 200 particles per generation at next steps [19,20].

3. Phage display libraries

3.1. Antibody phage libraries

Generally there are four kinds of antibody phage libraries: immune-library, naïve library, semi-synthetic and synthetic library [21–27]. In immune-library, the B-cells are isolated from the spleen of immunized animals and then the repertoires of manipulated V-genes are cloned into phage library vectors. The advantage of such library is that the affinity maturation has already occurred in the body of immunized animals and isolated antibodies have high affinity as well as specificity to their own antigen. However, there are some limitations that drawback the use of immune-libraries in phage display: need to construct new library for each antigen, high cost and laborious process, ethical issues due to use of animal for immunization and the target antigen must be immunogenic in *in vivo*. The mentioned limitations lead to introduction of different type of non-immune phage library known as single-pot library. Contrary to immune library that V-genes are from IgG mRNA, in naïve library, the V-gene sequences are from IgM mRNA of non-immunized animal. The synthetic libraries are created by combination of gene segment from un-rearranged antibody [28,29]. Synthetic libraries are based on diversity introduced into CDR (complementarity determining region) of antibody. The semi-synthetic libraries are built based on substitution of amino acids in CDR regions by PCR and constructing a library with high diversity that no exist in *in vivo* models [30].

4. Peptide phage library

There are three types of peptide phage libraries: linear heptapeptide library (Ph.D.-7), loop-constrained heptapeptide library (Ph.D.-C7C) and dodecapeptide library (Ph.D.-12). The displayed peptides on the surface of phage are small and therefore the infectivity of phage through pIII is not affected. Large diversity of combinatorial peptides displayed on the surface of the phages leads to isolation of different peptide to almost any type of targets [31]. Peptide libraries displayed on the surface of phages have many application: drug discovery, identification of ligand-binding activity, identification of biomarkers and epitope mapping [32–36].

5. Application of phage display

5.1. Production of monoclonal antibody by phage display

Hybridoma and phage display technology are common techniques to obtain monoclonal antibodies. Hybridoma technology has been presented by Georges Kohler and Cesar Milstein in 1975. Combination of B cell producing monoclonal antibody with mouse myeloma cells is the basis of hybridoma technology. Despite of advantage of hybridoma technology there are some limitation: poor immunogenicity of some targets, high production cost, unexpected immune response due to murine origin, time-consuming and need to myeloma cells [37–40]. Phage display is a powerful technique in isolation of monoclonal antibodies with high affinity to their target [41–44]. Summaries of steps of isolation of antibody using phage display are described as follow [39,40,45].

Production of gene fragment: This phase involves animal immunization with the desired antigen and then isolation of B lymphocytes, mRNA extraction and cDNA synthesis. The synthesized cDNA contain genetic information of all antibodies targeting various antigens and consist of approximately 10^9 to 10^{11} lymphocyte clones.

Cloning of gene fragments in the phagemid vectors: Genes related to the different clones of antibodies are digested with restriction enzymes, clone into phagemid vectors and then display on the surface of phages. Sequence diversity of the fragments at this step leads to optimum isolation of antibodies in the later steps. So far, a variety of phages like phages λ , T4, T7 and M13 have been described for displaying of antibody fragments. These vectors help to the displayed antibodies to maintain their function at the surface of phage. But using of phages like M13 that does not destroy the bacterial cells is most applicable. The phagemid vectors need helper phage to package and exit from the bacterial cells and enter to the medium [12,16,46].

Selection of specific phages: After cloning of the fragments into phagemid vectors, because of diversity in antibody gene, variety of clones of antibodies display on the surface of the phage. Selections of specific clone that recognize the antigen (target of interest) perform by biopanning. Since the antibody fragments on the surface of the phage are functional, the phage carrying specific antibody can be isolated from non-specific phages (due to antigen–antibody binding properties). At this step expressed antibodies on the surface of phage based on their ability to bind to the target antigen will be enriched through biopanning. The panning processes include: immobilization of antigen, binding of the phages, washing and removing non-

bonded phages, elution of the bonded phages, re-infection of the bacterial cells to amplify the eluted phages, purification of the recombinant phages and re-expression of antibodies on the surface of phage. Biopanning usually repeats 3 to 5 times to isolate specific antibodies with high affinity to target [47]. Different *in vitro* and *in vivo* models have been described for biopanning among which selection of phages based on antigen coated on solid phase is most common [12].

Screening: Isolation of antibodies with high affinity to target is the main aim of this step. Screening is performed using different methods like: immunoassay, immunocytochemistry, active isolation of cells due to their fluorescent properties and immunoblotting. In immunoassay, at first antigen is coated on solid phase, phage displaying antibody is added and then secondary antibody that detects the surface proteins of phages is added. After incubation and washing, the signal value and binding is measured in appropriate wave length [7].

6. Epitope mapping and finding mimotopes by phage display

Another application of phage display is to map epitope or binding site of antigen that is involved in interaction with antibody [36,48–50]. Peptide phage display libraries described in above are useful tools for identification of continuous or linear epitopes involving in interaction with antibody. Isolation and identification of mimotopes from peptide phage libraries is powerful approach to improve immunological studies in order to design and develop vaccine candidate [51–53]. Through peptide phage library and biopanning process, phages carrying peptides mimicking the epitopes of the antigen are identified. Length of epitopes that are recognized by antibodies is between four to six amino acids. So, heptapeptide libraries are appropriate for identification of all linear epitopes [54].

7. Concluding remarks

Phage display technique has application in monoclonal antibody production and epitope mapping. Monoclonal antibodies are useful tools in therapy, diagnosis and research. Epitope mapping can be improving immunological understanding, analysis the interaction site of antigen–antibody as well as vaccine design. Antibody phage library and peptide phage library played critical roles in development of potential diagnostic and therapeutic tools in various studies.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgment

This study was supported by Pasteur Institute of Iran.

References

- [1] Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. *Science* 1985; **228**: 1315-8.
- [2] Wilson DR, Finlay BB. Phage display: applications, innovations, and issues in phage and host biology. *Can J Microbiol* 1998; **44**(4): 313-29.
- [3] Malik P, Terry TD, Gowda LR, Langara A, Petukhov SA, Symmons MF, et al. Role of capsid structure and membrane protein processing in determining the size and copy number of peptides displayed on the major coat protein of filamentous bacteriophage. *J Mol Biol* 1996; **260**(1): 9-21.
- [4] Greenwood J, Willis AE, Perham RN. Multiple display of foreign peptides on a filamentous bacteriophage: peptides from *Plasmodium falciparum* circumsporozoite protein as antigens. *J Mol Biol* 1991; **220**(4): 821-7.
- [5] Weiss GA, Wells JA, Sidhu SS. Mutational analysis of the major coat protein of M13 identifies residues that control protein display. *Protein Sci* 2000; **9**(4): 647-54.
- [6] Sidhu SS, Lowman HB, Cunningham BC, Wells JA. Phage display for selection of novel binding peptides. *Method Enzymol* 2000; **328**: 333-5.
- [7] Barbas CF, Burton DR, Scott JK, Silverman GJ. *Phage display: a laboratory manual*. New York: CSHL Press; 2004.
- [8] Pande J, Szcwzyk MM, Grover AK. Phage display: concept, innovations, applications and future. *Biotechnol Adv* 2010; **28**(6): 849-58.
- [9] Smith GP, Schultz DA, Ladbury JE. A ribonuclease S-peptide antagonist discovered with a bacteriophage display library. *Gene* 1993; **128**(1): 37-42.
- [10] Arap MA. Phage display technology: applications and innovations. *Genet Mol Biol* 2005; **28**(1): 1-9.
- [11] Rakonjac J. *Filamentous bacteriophages: biology and applications*. Chichester: eLS. John Wiley & Sons Ltd; 2012. <http://dx.doi.org/10.1002/9780470015902.a0000777>.
- [12] Carmen S, Jermtus L. Concepts in antibody phage display. *Brief Funct Genomics Proteom* 2002; **1**(2): 189-203.
- [13] Endemann H, Model P. Location of filamentous phage minor coat proteins in phage and in infected cells. *J Mol Biol* 1995; **250**(4): 496-506.
- [14] Henry TJ, Pratt D. The proteins of bacteriophage M13. *Proc Natl Acad Sci* 1969; **62**(3): 800-7.
- [15] Russel M, Model P. Genetic analysis of the filamentous bacteriophage packaging signal and of the proteins that interact with it. *J Virol* 1989; **63**(8): 3284-95.
- [16] Stricker N, Li M. *Phage display technologies*. Chichester: eLS. John Wiley & Sons Ltd; 2001. <http://dx.doi.org/10.1038/npg.els.0000982>.
- [17] Pini A, Bracci L. Phage display of antibody fragments. *Curr Protein Pept Sci* 2000; **1**(2): 155-69.
- [18] Smith GP, Petrenko VA. Phage display. *Chem Rev* 1997; **97**(2): 391-410.
- [19] Hill HR, Stockley PG. Phage presentation. *Mol Microbiol* 1996; **20**(4): 685-92.
- [20] Webster R. Phage display of peptides and proteins: a laboratory manual. In: In Kay BK, Winter J, McCafferty J, editors. *Biology of the filamentous bacteriophage*. San Diego: Academic Press; 1996, p. 1-20.
- [21] Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. *Nat Biotechnol* 1996; **14**(3): 309-14.
- [22] Chassagne S, Laffly E, Drouet E, Hérodin F, Lefranc M-P, Thullier P. A high-affinity macaque antibody Fab with human-like framework regions obtained from a small phage display immune library. *Mol Immunol* 2004; **41**(5): 539-46.
- [23] Hoogenboom HR, de Bruine AP, Hufton SE, Hoet RM, Arends JW, Roovers RC. Antibody phage display technology and its applications. *Immunotechnology* 1998; **4**(1): 1-20.
- [24] Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization: human antibodies from V-gene libraries displayed on phage. *J Mol Biol* 1991; **222**(3): 581-97.
- [25] De Kruif J, Boel E, Logtenberg T. Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. *J Mol Biol* 1995; **248**(1): 97-105.
- [26] De Kruif J, Logtenberg T. Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. *J Biol Chem* 1996; **271**(13): 7630-4.

- [27] Barbas CF, Bain J, Hoekstra DM, Lerner RA. Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. *Proc Natl Acad Sci* 1992; **89**(10): 4457-61.
- [28] Willats WG. Phage display: practicalities and prospects. *Plant Mol Biol* 2002; **50**(6): 837-54.
- [29] Sidhu SS, Li B, Chen Y, Fellouse FA, Eigenbrot C, Fuh G. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. *J Mol Biol* 2004; **338**(2): 299-310.
- [30] Braunagel M. Construction of semisynthetic antibody libraries. *Recomb Antib Cancer Ther* 2003; **207**: 123-32.
- [31] Kohn J, Richard G, Hardev S. *Viral therapy of cancer*. New Jersey: Wiley online library. Ltd; 2008.
- [32] Gallop MA, Barrett RW, Dower WJ, Fodor SP, Gordon EM. Applications of combinatorial technologies to drug discovery. *J Med Chem* 1994; **37**(9): 1233-51.
- [33] Lam KS, Salmon SE. A new type of synthetic peptide library for identifying ligand-binding activity. *Nature* 1991; **354**(6348): 82.
- [34] Scott JK, Smith GP. Searching for peptide ligands with an epitope library. *Science* 1990; **249**(4967): 386-90.
- [35] Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. *Nature* 1996; **380**(6572): 364.
- [36] Luzzago A, Felici F, Tramontano A, Pessi A, Cortese R. Mimicking of discontinuous epitopes by phage-displayed peptides, I. Epitope mapping of human H ferritin using a phage library of constrained peptides. *Gene* 1993; **128**(1): 51-7.
- [37] Frenken LG, van der Linden RHJ, Hermans PWJ, Bos JW, Ruuls RC, de Geus B, et al. Isolation of antigen specific llama VHH antibody fragments and their high level secretion by *Saccharomyces cerevisiae*. *J Biotechnol* 2000; **78**(1): 11-21.
- [38] Brien PM, Aitken R. Antibody phage display: methods and protocols. In: Robert A, editor. *Methods in molecular biology*. New York: Humana Press; 2002, p. 178.
- [39] Lee CMY, Iorno N, Sierro F, Christ D. Selection of human antibody fragments by phage display. *Nat Protoc* 2007; **2**(11): 3001-8.
- [40] Barbas CF III. *Phage display: a laboratory manual*. New York: Cold Spring Harbor Laboratory Press; 2001.
- [41] Kazemi-Lomedasht F, Behdani M, Bagheri KP, Habibi-Anbouhi M, Abolhassani M, Arezumand R, et al. Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody. *Mol Immunol* 2015; **65**(1): 58-67.
- [42] Kazemi-Lomedasht F, Behdani M, Rahimpour A, Habibi-Anbouhi M, Poshang-Bagheri K, Shahbazzadeh D. Selection and characterization of specific Nanobody against human immunoglobulin G. *Monoclon Antib Immunodiagn Immunother* 2015; **34**(3): 201-5.
- [43] Homayouni V, Ganjalikhani-hakemi M, Rezaei A, Khanahmad H, Behdani M, Lomedasht FK. Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3). *Iran J Basic Med Sci* 2016; **19**(11): 1201.
- [44] Kazemi-Lomedasht F, Behdani M, Habibi-Anbouhi M, Shahbazzadeh D. Production and characterization of novel camel single domain antibody targeting mouse vascular endothelial growth factor. *Monoclon Antib Immunodiagn Immunother* 2016; **35**(3): 167-71.
- [45] O'Brien PM, Aitken R. In: Walker JM, editor. *Antibody phage display: methods and protocols*. New York: Humana Press; 2002.
- [46] Rondot S, Koch J, Breitling F, Dübel S. A helper phage to improve single-chain antibody presentation in phage display. *Nat Biotechnol* 2001; **19**: 75-8.
- [47] Hamzeh-Mivehroud M, Alizadeh AA, Morris MB, Church WB, Dastmalchi S. Phage display as a technology delivering on the promise of peptide drug discovery. *Drug Discov Today* 2013; **18**(23/24): 1144-57.
- [48] Jahdasani R, Jamnani FR, Behdani M, Habibi-Anbouhi M, Yardehnavi N, Shahbazzadeh D, et al. Identification of the immunogenic epitopes of the whole venom component of the *Hemiscorpius lepturus* scorpion using the phage display peptide library. *Toxicon* 2016; **124**: 83-93.
- [49] Fack F, Hüggle-Dörr B, Song D, Queitsch I, Petersen G, Bautz EK. Epitope mapping by phage display: random versus gene-fragment libraries. *J Immunol Method* 1997; **206**(1): 43-52.
- [50] Oleksiewicz M, Bøtner A, Toft P, Normann P, Storgaard T. Epitope mapping porcine reproductive and respiratory syndrome virus by phage display: the nsp2 fragment of the replicase polyprotein contains a cluster of B-cell epitopes. *J Virol* 2001; **75**(7): 3277-90.
- [51] Wang LF, Yu M. Epitope identification and discovery using phage display libraries: applications in vaccine development and diagnostics. *Curr Drug Targ* 2004; **5**(1): 1-15.
- [52] Gao J, Wang Y, Liu Z, Wang Z. Phage display and its application in vaccine design. *Ann Microbiol* 2010; **60**(1): 13-9.
- [53] Manoutcharian K, Terrazas LI, Gevorkian G, Acero G, Petrossian P, Rodriguez M, et al. Phage-displayed T-cell epitope grafted into immunoglobulin heavy-chain complementarity-determining regions: an effective vaccine design tested in murine cysticercosis. *Infect Immun* 1999; **67**(9): 4764-70.
- [54] Liu X, Hu Q, Liu S, Tallo LJ, Sadzewicz L, Schettine CA, et al. Serum antibody repertoire profiling using in silico antigen screen. *PLoS One* 2013; **8**(6): e67181.